Archives

Global Millennial Capital Raises USD 100 Million to Fund New-Age Technology Leaders in Underpenetrated Mid-Cap Segments

B GMCL’s IPO Opportunities Fund targets investments in AI, decentralized finance technologies and new-age energy solutions in companies with a market capitalization between USD 5… Login to continue reading Login…

Read MoreGlobal Millennial Capital Raises USD 100 Million to Fund New-Age Technology Leaders in Underpenetrated Mid-Cap Segments

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

B JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn’s disease who have… Login to continue reading Login…

Read MoreJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease

B TREMFYA® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI –… Login to continue reading Login…

Read MoreJohnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease